AU1648600A - Use of isatin derivatives as ion channel activating agents - Google Patents

Use of isatin derivatives as ion channel activating agents

Info

Publication number
AU1648600A
AU1648600A AU16486/00A AU1648600A AU1648600A AU 1648600 A AU1648600 A AU 1648600A AU 16486/00 A AU16486/00 A AU 16486/00A AU 1648600 A AU1648600 A AU 1648600A AU 1648600 A AU1648600 A AU 1648600A
Authority
AU
Australia
Prior art keywords
activating agents
disease
channel activating
spasms
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU16486/00A
Other languages
English (en)
Inventor
Philip K. Ahring
Palle Christophersen
Bo Skaaning Jensen
Tino Dyhring Jorgensen
Soren Peter Olesen
Dorte Strobaek
Lene Teuber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of AU1648600A publication Critical patent/AU1648600A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU16486/00A 1998-12-04 1999-12-03 Use of isatin derivatives as ion channel activating agents Abandoned AU1648600A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK199801608 1998-12-04
DKPA199801608 1998-12-04
PCT/DK1999/000679 WO2000033834A1 (en) 1998-12-04 1999-12-03 Use of isatin derivatives as ion channel activating agents

Publications (1)

Publication Number Publication Date
AU1648600A true AU1648600A (en) 2000-06-26

Family

ID=8106503

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16486/00A Abandoned AU1648600A (en) 1998-12-04 1999-12-03 Use of isatin derivatives as ion channel activating agents

Country Status (7)

Country Link
US (2) US20020016354A1 (enExample)
EP (1) EP1135123B1 (enExample)
JP (1) JP2002531498A (enExample)
AT (1) ATE285769T1 (enExample)
AU (1) AU1648600A (enExample)
DE (1) DE69922997T2 (enExample)
WO (1) WO2000033834A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2394292A1 (en) 2000-01-24 2001-08-02 Neurosearch A/S Isatine derivatives with neurotrophic activity
WO2002000222A1 (en) * 2000-06-26 2002-01-03 Novo Nordisk A/S Use of potassium channel agonists for the treatment of cancer
ATE291435T1 (de) * 2000-12-28 2005-04-15 Switch Biotech Ag Chlorzoxazon zur behandlung von psoriasis
WO2002064128A1 (en) * 2001-02-15 2002-08-22 Neurosearch A/S Treatment of diseases characterized by excessive or insufficient cell death
AR033095A1 (es) 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
US7148007B2 (en) * 2001-07-24 2006-12-12 Kabushiki Kaisha Toshiba Method for evaluating immunotoxicity of test substance
DE10250870A1 (de) * 2002-10-31 2004-05-13 Switch Biotech Ag Zusammensetzung enthaltend Aktivatoren von IK-Kaliumkanälen und Calcineurin-Antagonisten und deren Verwendung
FR2849773B1 (fr) * 2003-01-15 2006-07-14 Oreal Composition capillaire contenant un 2-alkylidene aminooxy-acetamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute
WO2004069213A2 (en) * 2003-01-15 2004-08-19 L'oreal Cosmetic composition comprising a 2-alkylideneaminooxyacetamide
SI1667678T1 (sl) 2003-10-03 2009-12-31 Veijlen N V Sestavek za ĺ˝ivalsko hrano
WO2005039546A2 (en) 2003-10-03 2005-05-06 Veijlen N.V. Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases
EP2061450B1 (en) 2006-09-13 2017-04-19 The Medical College of Wisconsin, Inc. Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases
US8232310B2 (en) * 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
JP5305704B2 (ja) * 2008-03-24 2013-10-02 富士フイルム株式会社 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版
US20120190009A1 (en) * 2010-12-14 2012-07-26 Fatah Kashanchi Viral Modulators and Processes Thereof
KR20130132932A (ko) 2010-12-20 2013-12-05 아스트라제네카 아베 2-카르복스아미드-4-피페라지닐-벤조푸란 유도체
MX377618B (es) 2012-04-12 2025-03-07 Univ Georgetown Métodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.
MX2016004678A (es) * 2013-10-24 2017-03-10 Univ Georgetown Composiciones para el tratamiento del cancer.
KR20160143792A (ko) * 2014-04-14 2016-12-14 플렉스 파마, 인크. 이온 통로 활성제 및 사용 방법
WO2015160842A1 (en) * 2014-04-14 2015-10-22 Flex Pharma, Inc. Methods and formulatiions of capsaicinoids and capsinoids
CN104130175A (zh) * 2014-06-13 2014-11-05 天津科技大学 不同位置取代吲哚酮类衍生物及其应用
EP3204376B1 (en) 2014-10-09 2023-04-19 Oncternal Therapeutics, Inc. Indolinone compounds and uses thereof
EP3436434B1 (en) 2016-03-31 2020-07-08 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
EP3490553B1 (en) 2016-07-29 2024-08-28 Oncternal Therapeutics, Inc. Combination comprising an indolinone compound and its use in the treatment of lymphoma
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
WO2018136943A1 (en) 2017-01-23 2018-07-26 Flex Pharma, Inc. Compositions and methods affecting exercise performance
CN108017570A (zh) * 2017-12-21 2018-05-11 常州大学 一种靛红的生产方法
CN108721297A (zh) * 2018-05-15 2018-11-02 泰山医学院 一种减轻免疫抑制的抗肿瘤药物及其应用
CN108403690A (zh) * 2018-05-15 2018-08-17 泰山医学院 一种抑制黑色素瘤细胞增殖的药物及其应用
CN113564623A (zh) * 2021-06-17 2021-10-29 福建师范大学 电化学氧化n-取代吲哚衍生物制备靛红化合物的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR65270B (en) * 1978-10-10 1980-07-31 Fujisawa Pharmaceutical Co Isatin derivatives and processes for the preparation thereof
US4322533A (en) * 1980-03-17 1982-03-30 Lesher George Y 1H-Indole-2,3-dione derivatives
US4780477A (en) * 1985-06-08 1988-10-25 Kissei Pharmaceutical Co., Ltd. Isatin compositions having anti-ulcer activities
GB8816944D0 (en) * 1988-07-15 1988-08-17 Sobio Lab Compounds
IE69677B1 (en) * 1989-12-11 1996-10-02 Neurosearch As Isatine derivatives their preparation and use
US5192792A (en) 1990-12-07 1993-03-09 Warner-Lambert Company Isatine derivatives, and their method of use
US5312928A (en) * 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
US5514690A (en) * 1992-11-17 1996-05-07 E. R. Squibb & Sons, Inc. Aminocarbonyl (thiocarbonyl) and cyanoguanidine derivatives of quinoline and indoline
TW281669B (enExample) * 1993-02-17 1996-07-21 Chugai Pharmaceutical Co Ltd
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
EP1002535A1 (en) * 1998-10-28 2000-05-24 Hrissanthi Ikonomidou New use of glutamate antagonists for the treatment of cancer

Also Published As

Publication number Publication date
US20020016354A1 (en) 2002-02-07
JP2002531498A (ja) 2002-09-24
DE69922997D1 (de) 2005-02-03
US6969729B2 (en) 2005-11-29
WO2000033834A1 (en) 2000-06-15
ATE285769T1 (de) 2005-01-15
EP1135123B1 (en) 2004-12-29
DE69922997T2 (de) 2005-12-15
US20030114513A1 (en) 2003-06-19
EP1135123A1 (en) 2001-09-26

Similar Documents

Publication Publication Date Title
AU1648600A (en) Use of isatin derivatives as ion channel activating agents
AU4768999A (en) Potassium channel blocking agents
EP2690092B1 (en) Deuterated isoindoline-1,3-dione derivatives as PDE4 and TNF-alpha inhibitors
JP2002531552A5 (enExample)
MX2009003142A (es) Derivados de indazolilo utiles como agentes moduladores del canal de potasio.
WO2005123692A8 (en) Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors
EP1332131A2 (en) Acid derivatives useful as serine protease inhibitors
CA2487365A1 (en) Piperidine derivatives as potassium channel blockers
JP2015527336A (ja) ピペラジノトリアゾール化合物及びその製造方法と製薬用途
WO2001019802A1 (fr) Composes cycliques aromatiques azotes a six elements
JP2008520745A5 (enExample)
EP2982668A3 (en) 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors for the treatment of thromboembolic disorders
EP2817288A2 (en) Processes for the preparation of (s)-1-(3-ethoxy-4methoxyphenyl)-2-methanesulfonylethylamine
CN103492372A (zh) 调节雄激素受体的甲酰胺类化合物
WO2002066672A3 (en) Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
Balzarini et al. Synthesis and antiviral activity of the enantiomeric forms of carba-5-iodo-2'-deoxyuridine and carba-(E)-5-(2-bromovinyl)-2'-deoxyuridine
CA2498291A1 (en) Diazabicyclic compounds useful in the treatment of cns and other disorders
CY1107763T1 (el) Εναντιομερεις ενωσεις για την αγωγη καρδιακων αρρυθμιων και μεθοδοι χρησεως
MXPA03012045A (es) Proceso para preparar derivados del acido 7-amino sin 3,5-dihidroxi heptanoico a traves de derivados del acido 6-ciano sin 3,5-dihidroxi hexanoico.
Xu et al. Multifunctional 5, 6-dimethoxybenzo [d] isothiazol-3 (2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer’s disease
SK4222001A3 (en) 2,3-disubstituted pyridine derivatives, process for the preparation thereof, drug compositions containing the same and intermediates for the preparation
JP2002531539A5 (enExample)
WO2001079209A3 (en) Diazafluorenone il-8 antagonists
UA97837C2 (ru) Соединения хинолина для лечения нарушений, которые реагируют на модуляцию рецептора серотонина 5-ht6
WO2006011024A3 (en) New tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase